Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets such as agricultural biotechnology. Fluidigm’s systems consist of instruments, software, integrated fluidic circuits (IFCs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. Fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. The Company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. Fluidigm actively markets nine different commercial chips, a growing line of assays and primers, the BioMark HD™ and EP1™ analytical instrument platforms for gene expression and genotyping, and the Access Array™ system designed to streamline sample preparation costs in targeted DNA resequencing applications.
Based in South San Francisco, Fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including stock options.
Specialties
integrated fluidic circuits, IFC
New hires at Fluidigm Corporation
-
-
Interim Corporate Controller
Came from...
Life Technologies (formerly Applied Biosystems, Inc.), Director Accounting Operations
-
-
-
APAC Channel Manager
Came from...
Illumina, Asia Pacific Senior Market Development Manager/Sales Specialist
Fluidigm Corporation Activity on LinkedIn
-
Fluidigm Corporation has a new Facilities Manager
Les Winchester is now Facilities Manager
-
-
-
-
-
Fluidigm Corporation has a new Interim Corporate Controller
Todd Lee is now Interim Corporate Controller
